Axitinib in metastatic renal cell carcinoma.

Abstract

Axitinib is the most recent targeted therapy approved by the US FDA and EMA in the treatment of metastatic renal cell carcinoma (mRCC). It is a second-generation, orally available, potent tyrosine kinase inhibitor targeting selectively VEGF receptor (VEGFR)-1, -2 and -3, resulting in inhibition of angiogenesis, metastasis and tumor growth. Based on the results of a randomized pivotal Phase III clinical trial, axitinib stands as one of the two recommended agents for patients with mRCC who progressed after first-line tyrosine kinase inhibitor therapy. Its potent and selective inhibition of VEGFR was the rationale for its development in the second-line setting after failure of prior cytokines or sunitinib. Here we examine the preclinical and clinical data of axitinib for mRCC, and its use in the treatment algorithm.

• Authors: Laurence Albiges, Marco Gizzi, Edith Carton, Bernard Escudier
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 15 Issue 5 Pg. 499-507 (May 2015) ISSN: 1744-8328 [Electronic] England
• PMID: 25907705 (Publication Type: Journal Article, Review)

Chemical References

• Imidazoles
• Indazoles
• Protein Kinase Inhibitors
• Axitinib
• Receptors, Vascular Endothelial Growth Factor

Topics

• Algorithms
• Axitinib
• Carcinoma, Renal Cell (drug therapy, pathology)
• Disease Progression
• Humans
• Imidazoles (pharmacology, therapeutic use)
• Indazoles (pharmacology, therapeutic use)
• Kidney Neoplasms (drug therapy, pathology)
• Molecular Targeted Therapy
• Neoplasm Metastasis
• Protein Kinase Inhibitors (pharmacology, therapeutic use)
• Randomized Controlled Trials as Topic
• Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)